Member? Log in...

Join or renew today

Latest Reports/Studies

Institute of Medicine: The Future of Drug Safety

In its report, The Future of Drug Safety: Promoting and Protecting the Health of the Public (Sept. 22, 2006), an IOM committee considered the drug safety system as the sum of all activities conducted by FDA and other stakeholders to monitor, evaluate, improve, and ensure drug safety.

Although much of the committee's work was focused around the drug review, safety surveillance, and related activities of the Center for Drug Evaluation and Research (CDER), the committee also reviewed some key aspects of the roles and considered the potential contributions of the pharmaceutical industry, the academic research enterprise, Congress, the health care delivery system, patients and the public.